VYNE Therapeutics (NASDAQ:VYNE) Upgraded by Wall Street Zen to Sell Rating

Wall Street Zen upgraded shares of VYNE Therapeutics (NASDAQ:VYNE) to a sell rating in a research note released on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VYNE Therapeutics in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, VYNE Therapeutics has a consensus rating of “Reduce” and an average price target of $4.50.

VYNE Therapeutics Price Performance

VYNE Therapeutics stock opened at $0.59 on Friday. VYNE Therapeutics has a 1 year low of $0.28 and a 1 year high of $4.30. The firm’s 50 day moving average price is $0.38 and its 200-day moving average price is $0.60. The stock has a market cap of $19.51 million, a P/E ratio of -0.75 and a beta of 1.99.

VYNE Therapeutics (NASDAQ:VYNE) last issued its earnings results on Thursday, November 6th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.13 million. VYNE Therapeutics had a negative net margin of 6,425.19% and a negative return on equity of 80.84%. As a group, equities analysts expect that VYNE Therapeutics will post -0.97 EPS for the current year.

Institutional Trading of VYNE Therapeutics

A number of large investors have recently made changes to their positions in VYNE. Baker BROS. Advisors LP purchased a new stake in shares of VYNE Therapeutics during the 3rd quarter valued at about $285,000. DAFNA Capital Management LLC purchased a new stake in VYNE Therapeutics during the first quarter valued at approximately $1,005,000. Kennedy Capital Management LLC bought a new stake in shares of VYNE Therapeutics in the 2nd quarter valued at approximately $942,000. Shay Capital LLC bought a new stake in shares of VYNE Therapeutics in the 3rd quarter valued at approximately $165,000. Finally, Acorn Capital Advisors LLC boosted its holdings in shares of VYNE Therapeutics by 72.0% in the 1st quarter. Acorn Capital Advisors LLC now owns 785,938 shares of the company’s stock worth $1,242,000 after purchasing an additional 328,968 shares during the period. 83.78% of the stock is currently owned by institutional investors.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.